Rapid and Inexpensive Biochip-Based Allergy Testing

Gentel BioSurFaces(Gentel)致力于确定过敏原生物芯片的技术优势和可行性，作为一种快速、廉价和易于使用的体外方法，用于识别血清中升高的过敏原特异性IgE滴度。这种生物芯片以均匀的金表面为基础，可进行化学修饰，并采用独特的微通道技术(阵列2微通道)。片上微通道允许同时研究许多谨慎的交互作用，并允许快速、片上生成标准曲线。定量是以类似于酶联免疫吸附分析(ELISA)的方式获得的。这些技术结合在一起，使Gentel能够开发一种强大的过敏原生物芯片，可用于快速定量血清中过敏原特异性IgE滴度。这种生物芯片将在临床和研究领域找到应用，包括但不限于过敏原特异性IgE 人类患者的概况，动物模型中疫苗和治疗性抗体效力的监测，抗原性测定和抗体群体的定位。 该建议的目的是：(1)选择最佳的表面化学物质，用于通过目标IgE的最高、特异性结合来衡量过敏原的附着；(2)开发和确定最佳表面化学物质，以阻断人血清成分在阵列表面的非特异性吸附，如通过最高信噪比来测量；以及(3)验证所提出的过敏原生物芯片定量测定过敏原特异性IgE滴度的能力 我们的创新阵列“通过将结果与酶联免疫吸附试验获得的结果进行比较。 后续的第二阶段提案将扩大测试的过敏原数量，并通过将样品纯化与生物芯片相结合来进一步开发我们的阵列2微流控技术。这将使全血直接应用于生物芯片，并实现廉价的芯片读取过敏测试，周转时间约为一小时。

GenTel BioSurfaces (GenTel) seeks to establish the technical merit and feasibility of an allergen biochip for use as a rapid, inexpensive and easy-to-use in vitro method for identifying elevated allergen-specific IgE titers in serum. This biochip is based upon a uniform gold surface that is highly amenable to chemical modification and uses a unique microchannel technology (Array 2 Microchannels). On-chip microchannels enable many discreet interactions to be studied simultaneously and allow rapid, on-chip generation of a standard curve. Quantification is obtained in an analogous manner to an enzyme linked immunosorbent assays (ELISAs). Together, these technologies allow GenTel to develop a robust allergen biochip that can be used to rapidly quantitate allergen-specific IgE titers in serum. This biochip will find applications in the clinical and research communities including, but not limited to, allergen-specific IgE profiling of human patients, monitoring vaccine and therapeutic antibody efficacy in animal models, antigenic determination and localization of antibody populations. The objectives of this proposal are to: (1) Select optimal surface chemistry for attachment of allergens as measure by the highest, specific binding of target IgE; (2) develop and determine optimal surface chemistry for blocking non-specific adsorption of human serum components to the array surface as measured by the highest signal: noise ratio and (3) to validate the ability of the proposed allergen biochip to quantitatively determine the titer of an allergen-specific IgE using our innovative Array" Microchannels by comparing the results to those obtained by ELISA. A follow-up Phase II proposal will broaden the number of allergens tested and further develop our Array 2 Microfluidics technology by integrating sample purification with the biochip. This will enable direct application of whole blood to the biochip and an inexpensive chip-reading allergy test with a turnaround time of about one hour.